Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia.

Internal medicine journal - 1 Feb 2012

Sulda M L, Kuss B J, Hall R K, Bailey S, Macardle P J

Abstract excerpt

BACKGROUND: Chronic lymphocytic leukaemia (CLL) is a clinically heterogeneous disease. While immunoglobulin variable region heavy chain (IgVH) mutational status remains the 'gold standard' in molecular prognostication, a range of additional markers is increasingly being used in clinical trials. As awareness of trial data increases, requests to determine these prognostic markers for new CLL patients are becoming...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Flow Cytometry

Share to Immunoglobulin Variable Region

Share to Interleukin-2 Receptor alpha Subunit

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Source

Identifiers

PMID: 20561095
DOI: 10.1111/j.1445-5994.2010.02294.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia.PMID 20561095Read ↗

CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.Semantic proximity Read ↗

Implications of new prognostic markers in chronic lymphocytic leukemiaSemantic proximity Read ↗

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted TherapySemantic proximity Read ↗

Implications of new prognostic markers in chronic lymphocytic leukemia.Semantic proximity Read ↗

Molecular biomarkers in chronic lymphocytic leukemia.Semantic proximity Read ↗

Immunogenetics of chronic lymphocytic leukemia.Semantic proximity Read ↗

Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia.Semantic proximity Read ↗

Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.Semantic proximity Read ↗

Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel DrugsSemantic proximity Read ↗

Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?Semantic proximity Read ↗

Prognostic markers in chronic lymphocytic leukemia: a comprehensive review.Semantic proximity Read ↗

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.